Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. — Investor Relations & Filings

Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 414 across all filing types
Latest filing 2026-03-27 Major Shareholding Noti…
Country KR South Korea
Listing KO 179530

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 87% confidence The document is a Korean "주식등의 대량보유상황보고서(약식)", which translates to a large shareholding status report. It details the reporting of a substantial shareholding (over threshold) by an investor (Espacio 조합), including previous and current holdings, voting rights, and reasons for the change (conversion bond early repayment). This matches the definition of a Major Shareholding Notification (Code: MRQ).
2026-03-27 Korean
주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 85% confidence The document is a Korean ‘주요사항보고서’ (Major Item Report) filed with the stock exchange regarding a decision to sell self-convertible bonds, detailing bond terms, sale decision date, sale amount, early redemption options, and purchaser information. This is a financing activity announcement covering a capital structure change (convertible bond financing). It therefore falls under Capital/Financing Update (CAP), not an annual/interim report or a securities issuance of equity shares (SHA), but a debt financing update.
2026-03-27 Korean
주요사항보고서(자기전환사채만기전취득결정)
Capital/Financing Update Classification · 75% confidence The document is a Korean "주요사항보고서" (material event report) filed with the Korea Exchange and Financial Services Commission announcing the company’s decision to acquire its own convertible bonds before maturity. This is a corporate financing activity and change in capital structure rather than a share buyback or dividend. Therefore it best fits the “Capital/Financing Update” category.
2026-03-25 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 99% confidence The document is titled “감사보고서” (Audit Report) and contains the independent auditor’s opinion, detailed audit procedures, and the company’s audited financial statements (balance sheet, income statement, cash flow, notes) for the years ended 2025 and 2024. It is a standalone audit report and financial statements, not a full annual management discussion or regulatory filing announcement. This fits the definition of a standalone Audit Report (excluding a full Annual Report). FY 2025
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 92% confidence The document is titled “감사보고서 제출” (“Audit Report Submission”) and contains detailed auditor’s opinions, consolidated and separate financial statements, audit findings by our accounting firm, and related financial data. It is not merely an announcement of publication but the actual audit report content. This matches the definition of a standalone audit report (Code AR). FY 2025
2026-03-23 Korean
주주총회소집공고
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for AdBiotech Co., Ltd. It includes the meeting date, location, agenda items (such as financial statement approval and board/auditor compensation), and detailed management information regarding board activities and business outlook. This document is a standard proxy statement/notice for an upcoming Annual General Meeting (AGM).
2026-03-16 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.